GeoVax Labs, Inc. (Nasdaq: GOVX) announced a strategic shift to prioritize its lead programs, GEO-MVA and Gedeptin, while discontinuing development of its GEO-CM04S1 COVID-19 vaccine candidate. The decision, driven by the evolving market landscape, allows the company to concentrate resources on programs with clearer regulatory pathways and stronger commercialization potential.
The COVID-19 vaccine discontinuation was not due to safety concerns but reflects “the continued evolution and contraction of the global COVID-19 vaccine market,” according to the company. GeoVax emphasized that portfolio prioritization is standard in the biotechnology industry, enabling alignment with highest-value opportunities.
David Dodd, Chairman and CEO of GeoVax, stated: “GeoVax is at an important inflection point, and this decision reflects a deliberate and disciplined focus on the programs we believe can deliver the greatest near-term and long-term value.” He added that GEO-MVA is advancing toward clinical validation and potential commercialization, while Gedeptin gains relevance in immuno-oncology.
GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine targeting mpox and smallpox, is progressing under an expedited regulatory pathway supported by European Medicines Agency (EMA) scientific advice. The pathway enables potential approval based on a single pivotal immunobridging study demonstrating non-inferiority to an approved MVA vaccine, significantly accelerating timelines. Clinical-grade material has been manufactured, and the company plans to initiate a Phase 3 immunobridging study in the second half of 2026. Following success, GEO-MVA could advance toward regulatory submission and potential Emergency Use Licensing.
GeoVax has initiated outreach with global procurement and preparedness stakeholders, including government agencies and biodefense programs, to secure potential vaccine supply agreements. These efforts aim to position GEO-MVA as a critical additional MVA vaccine supplier, supporting supply-chain resilience and biodefense preparedness.
In oncology, Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) platform, is being advanced in alignment with evolving treatment paradigms. The landmark KEYNOTE-689 Phase 3 trial demonstrated improved event-free survival with neoadjuvant checkpoint inhibitor therapy in resectable head and neck cancers, highlighting the potential for Gedeptin combinations. GeoVax’s planned Phase 2 study (AdPNP-203) will evaluate Gedeptin in combination with pembrolizumab and fludarabine in a neoadjuvant setting, aiming to enhance tumor immune visibility and improve outcomes.
Gedeptin’s mechanism is designed to damage treated lesions through localized generation of a potent chemotherapeutic agent and sensitize tumors to checkpoint inhibitors by exposing neoantigens. This may expand response rates and improve durability in patients with limited benefit from checkpoint inhibition alone.
Dodd concluded: “By concentrating our efforts on GEO-MVA and maintaining our oncology innovation with Gedeptin, we believe we are positioning the Company for a more focused, execution-driven path toward late-stage development, commercialization and long-term value creation.”
For more information, visit GeoVax's website.
